Cargando…
Prevalence and Pattern of Neurocognitive Impairment in Nigerians with Stages 3 to 5 Chronic Kidney Disease
Background. Cognitive impairment with its negative effect on quality of life has been reported in chronic kidney disease (CKD). The paucity of the literature on cognitive impairment in Africans with CKD prompted this study. Objectives. To determine the frequency and pattern of cognitive impairment i...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706068/ https://www.ncbi.nlm.nih.gov/pubmed/23864958 http://dx.doi.org/10.1155/2013/374890 |
_version_ | 1782476509453221888 |
---|---|
author | Williams, U. E. Owolabi, M. O. Ogunniyi, A. Ezunu, E. O. |
author_facet | Williams, U. E. Owolabi, M. O. Ogunniyi, A. Ezunu, E. O. |
author_sort | Williams, U. E. |
collection | PubMed |
description | Background. Cognitive impairment with its negative effect on quality of life has been reported in chronic kidney disease (CKD). The paucity of the literature on cognitive impairment in Africans with CKD prompted this study. Objectives. To determine the frequency and pattern of cognitive impairment in patients with stages 3 to 5 CKD. Methods. We studied 79 consecutive consenting adults with a National Kidney Foundation (NKF) stage 3 to 5 CKD based on their estimated glomerular filtration rate using the Cockcroft-Gault formula. The controls consisted of healthy demographically matched subjects. Community screening instrument for dementia (CSI'D), trail making test A (TMTA), and trail making test B (TMTB) were used for cognitive assessment. Results. More CKD patients had cognitive impairment compared with controls using CSI'D (51.9% versus 2.5%, P < 0.001); TMTA (53.2% versus 0%, P < 0.001); and TMTB (40% versus 0%, P < 0.001). The odds of having cognitive impairment increased in the presence of CKD when assessed using CSI'D (OR = 2.026; CI = 1.607–2.555); TMTA (OR = 3.13; CI = 2.40–4.09) and TMTB (OR = 3.22; CI = 2.42–4.25). CKD patients performed poorer on tests of executive function TMTA (P < 0.001) and TMTB (P < 0.001) while CSI'D showed significantly lower scores on multiple cognitive domains. Conclusions. Significant cognitive impairment in multiple domains exists among Nigerians with CKD. |
format | Online Article Text |
id | pubmed-3706068 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-37060682013-07-17 Prevalence and Pattern of Neurocognitive Impairment in Nigerians with Stages 3 to 5 Chronic Kidney Disease Williams, U. E. Owolabi, M. O. Ogunniyi, A. Ezunu, E. O. ISRN Neurol Research Article Background. Cognitive impairment with its negative effect on quality of life has been reported in chronic kidney disease (CKD). The paucity of the literature on cognitive impairment in Africans with CKD prompted this study. Objectives. To determine the frequency and pattern of cognitive impairment in patients with stages 3 to 5 CKD. Methods. We studied 79 consecutive consenting adults with a National Kidney Foundation (NKF) stage 3 to 5 CKD based on their estimated glomerular filtration rate using the Cockcroft-Gault formula. The controls consisted of healthy demographically matched subjects. Community screening instrument for dementia (CSI'D), trail making test A (TMTA), and trail making test B (TMTB) were used for cognitive assessment. Results. More CKD patients had cognitive impairment compared with controls using CSI'D (51.9% versus 2.5%, P < 0.001); TMTA (53.2% versus 0%, P < 0.001); and TMTB (40% versus 0%, P < 0.001). The odds of having cognitive impairment increased in the presence of CKD when assessed using CSI'D (OR = 2.026; CI = 1.607–2.555); TMTA (OR = 3.13; CI = 2.40–4.09) and TMTB (OR = 3.22; CI = 2.42–4.25). CKD patients performed poorer on tests of executive function TMTA (P < 0.001) and TMTB (P < 0.001) while CSI'D showed significantly lower scores on multiple cognitive domains. Conclusions. Significant cognitive impairment in multiple domains exists among Nigerians with CKD. Hindawi Publishing Corporation 2013-06-20 /pmc/articles/PMC3706068/ /pubmed/23864958 http://dx.doi.org/10.1155/2013/374890 Text en Copyright © 2013 U. E. Williams et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Williams, U. E. Owolabi, M. O. Ogunniyi, A. Ezunu, E. O. Prevalence and Pattern of Neurocognitive Impairment in Nigerians with Stages 3 to 5 Chronic Kidney Disease |
title | Prevalence and Pattern of Neurocognitive Impairment in Nigerians with Stages 3 to 5 Chronic Kidney Disease |
title_full | Prevalence and Pattern of Neurocognitive Impairment in Nigerians with Stages 3 to 5 Chronic Kidney Disease |
title_fullStr | Prevalence and Pattern of Neurocognitive Impairment in Nigerians with Stages 3 to 5 Chronic Kidney Disease |
title_full_unstemmed | Prevalence and Pattern of Neurocognitive Impairment in Nigerians with Stages 3 to 5 Chronic Kidney Disease |
title_short | Prevalence and Pattern of Neurocognitive Impairment in Nigerians with Stages 3 to 5 Chronic Kidney Disease |
title_sort | prevalence and pattern of neurocognitive impairment in nigerians with stages 3 to 5 chronic kidney disease |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706068/ https://www.ncbi.nlm.nih.gov/pubmed/23864958 http://dx.doi.org/10.1155/2013/374890 |
work_keys_str_mv | AT williamsue prevalenceandpatternofneurocognitiveimpairmentinnigerianswithstages3to5chronickidneydisease AT owolabimo prevalenceandpatternofneurocognitiveimpairmentinnigerianswithstages3to5chronickidneydisease AT ogunniyia prevalenceandpatternofneurocognitiveimpairmentinnigerianswithstages3to5chronickidneydisease AT ezunueo prevalenceandpatternofneurocognitiveimpairmentinnigerianswithstages3to5chronickidneydisease |